GlobeNewsWire·Jun 22, 2026
InterCure Secures NIS 22 Million in Private Placement Financing Led by Leading Pharma-Focused Hedge FundsNEW YORK & HERZLIYA, Israel, June 22, 2026 (GLOBE NEWSWIRE) -- InterCure Ltd. (Nasdaq: INCR) (TASE: INCR) (dba Canndoc) (“InterCure” or the “Company”), today announced that, further to the Company's prior reports regarding growing demand in Germany and opportunities arising from the recent U.S. federal rescheduling of cannabis, the Company has entered into a binding term sheet providing for funding commitments of NIS 22 million (approximately US$7.4 million), which may increase to NIS 54 million (approximately US$18.6 million) (the “Private Placement”).
